BioLife Solutions (BLFS)

• Market cap: $1.24B
• 1 day: -3.05%
• 5 days: -3.30%
• 1 month: -2.95%
• 3 months: 5.04%
• 6 months: 3.69%
• Year to date: 1.87%
• 1 year: 52.40%
• 5 years: 70.63%
• 10 years: 1,140.47%
• Sector: Healthcare
• Industry: Electromedical & Electrotherapeutic Apparatus

About: BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.

Employees: 414

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

10% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 59

7% more capital invested

Capital invested by funds: $1.14B [Q3] → $1.21B (+$76M) [Q4]

2.34% more ownership

Funds ownership: 98.54% [Q3] → 100.88% (+2.34%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

7% less funds holding

Funds holding: 193 [Q3] → 179 (-14) [Q4]

31% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 32

34% less call options, than puts

Call options by funds: $122K | Put options by funds: $184K

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $30 12% upside
• Avg. target: $31 17% upside
• High target: $33 24% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Northland Capital Markets Carl Byrnes 100% 1-year accuracy 6 / 6 met price target	16% upside $31	Outperform Maintained	8 Jan 2025
Benchmark Robert Wasserman 60% 1-year accuracy 30 / 50 met price target	12% upside $30	Buy Reiterated	19 Dec 2024
Keybanc Paul Knight 33% 1-year accuracy 3 / 9 met price target	24% upside $33	Overweight Maintained	13 Dec 2024